Monte Rosa Therapeutics (GLUE) Cash from Operations Growth (1y) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.29 Bn | 1.61 Bn | - | 17.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.86% |
| Dec 31, 2025 | -133.36% |
| Sep 30, 2025 | 578.37% |
| Jun 30, 2025 | -25.04% |
| Mar 31, 2025 | -19.20% |
| Dec 31, 2024 | 335.05% |
| Sep 30, 2024 | 15.02% |
| Jun 30, 2024 | -9.65% |
| Mar 31, 2024 | -63.06% |
| Dec 31, 2023 | 223.68% |
| Sep 30, 2023 | -19.93% |
| Jun 30, 2023 | -23.53% |
| Mar 31, 2023 | 14.59% |
| Dec 31, 2022 | -69.07% |
| Sep 30, 2022 | -15.77% |
| Jun 30, 2022 | -50.94% |
| Mar 31, 2022 | -98.36% |
| Dec 31, 2021 | -65.29% |
| Sep 30, 2021 | -158.22% |